Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -15.62
- Piotroski Score 3.00
- Grade Speculative Buy
- Symbol (BIOL)
- Company BIOLASE, Inc.
- Price $0.02
- Changes Percentage (27.39%)
- Change -$0
- Day Low $0.02
- Day High $0.05
- Year High $1.94
BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode soft-tissue laser systems for soft tissue, pain therapy, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces, and teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California.
- Last Earnings 06/16/2005
- Ex-Dividend for 5/16 Dividend 06/24/2005
- Dividend Payable 07/12/2005
- Today N/A
- Next Earnings (Estimated) 11/06/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$11.97
- Trailing P/E Ratio -0.01
- Forward P/E Ratio -0.01
- P/E Growth -0.01
- Net Income $-20,632,000
Income Statement
Quarterly
Annual
Latest News of BIOL
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Frogs in Yosemite lakes died, the entire ecosystem collapsed. But biology brought them back
For over a century, Yosemite's High Sierra lakes suffered from non-native fish stocking, leading to the decline of the Sierra Nevada Yellow-legged frogs. Researchers, after finding fungus-resistant fr...
By USA Today | 2 days ago -
BioLife Solutions Inc (BLFS) Q3 2024 Earnings Call Highlights: Strategic Divestitures and ...
The earnings call transcript details post-SSAE sale financials, with 60% adjusted gross margin and 13% EBITDA for the first half of 2024. Future growth is expected in 2025, focusing on cell processing...
By Yahoo! Finance | 5 days ago -
Q3 2024 ADMA Biologics Inc Earnings Call
ADMA Biologics had a successful quarter with strong financial results and corporate updates. The company expects continued growth driven by ASCENIV. Plans for yield enhancement, SG-001 program progres...
By Yahoo! Finance | 1 week ago
